Aims Changes in both digoxin and aciclovir renal clearance following coadministration with some other renally eliminated drugs have been reported. The potential interaction of valaciclovir, with its antiherpetic metabolite aciclovir, and digoxin was investigated. Methods Twelve healthy volunteers (seven males, five females) participated in an open, randomized, four-period crossover study. Valaciclovir, 1000 mg, was given alone on one occasion, and on another, after the second of two 0.75 mg digoxin doses administered 12 h apart. Blood samples and all urine were collected up to 12 h following the valaciclovir dose for aciclovir radioimmunoassay. On a third occasion, digoxin was given alone and on a fourth, with 1000 mg valaciclovir three times/day for 8 days starting 12 h before the first digoxin dose. Blood samples were taken up to 168 h and all urine collected up to 24 h following the second dose for digoxin radioimmunoassay. Results There were no clinically significant differences in digoxin or aciclovir pharmacokinetic parameters when digoxin or valaciclovir was given alone or in combination.
Introduction Methods
Valaciclovir (Valtrex@), the l-valyl ester of aciclovir, is Subjects licensed for the treatment of herpes zoster (shingles), a disease occurring commonly in the elderly. After oral Twelve healthy volunteers (seven males, five females) of mean age 31 years (range 22-44 years) and mean weight administration, valaciclovir is rapidly converted to aciclovir with a bioavailability 3-5 times greater than from oral 75 kg (range 51-99 kg ) participated in the study. Exclusion criteria included evidence of a cardiac conduction disorder aciclovir [1] . Aciclovir is renally eliminated with tubular secretion forming a significant component. Probenecid, on a 12-lead ECG and an estimated creatinine clearance <70 ml min −1 . All subjects gave written informed consent, which inhibits organic anion secretion in the renal tubule, decreases the renal clearance of aciclovir [2] . Both probenecid and the protocol was approved by the Wellcome Protocol Review Committee and the King's Healthcare Research and cimetidine, which inhibit tubular cation secretion, decrease aciclovir renal clearance following oral valaciclovir Ethics Committee.
Digoxin, a drug of low therapeutic index, is commonly Study design prescribed in the elderly. In most patients more than 80%
This open, randomized, four-period crossover study was of digoxin is excreted unchanged in the urine [4] .
carried out at the Wellcome Clinical Investigations Unit, Interactions with drugs which affect digoxin renal clearKing's College Hospital, London. Volunteers fasted overnight ance have been identified, some of which may be due to prior to drug administration on the first blood sampling day. effects on tubular secretion [5, 6] . As there is the potential Oral valaciclovir, 1000 mg, was administered on one for an interaction between digoxin and aciclovir followoccasion, and on another, with digoxin, 0.75 mg being ing oral valaciclovir, we have studied the pharmacokinetics given 12 h before and 0.75 mg being given with valaciclovir. of the drugs alone and in combination in healthy Digoxin was not dosed to steady state because of the ethical volunteers.
concerns of giving multiple doses to healthy volunteers. valaciclovir dose for plasma aciclovir assay. Urine was also collected up to 12 h, weighed and a 10 ml aliquot was by the linear trapezoidal rule. AUC(0, 2) was calculated as AUC(0, t)+Ct/l z where C t is the last quantifiable concenfrozen at −20°C for aciclovir assay.
Digoxin was administered as 2×0.75 mg doses alone on tration at time t. l z was obtained by log linear regression, using the terminal portion of the log of the concentrationone occasion, and on another, with oral valaciclovir, 1000 mg three times daily for 8 days, with valaciclovir time curve. Digoxin C max and AUC(0, 2) were corrected for pre-dose concentration (C 0 ) as the plasma profile after started 12 h before the first digoxin dose. The valaciclovir daily dose was that recommended for the treatment of the second dose was not at steady state (half-life of approximately 40 h). Digoxin AUC(0, 24 h) was also shingles. Blood samples were taken before and 0.5, 1.0, 1.5, 2.0, 2. 5, 3.0, 4.0, 6.0, 8.0, 12, 24, 32, 48, 72, 96 and 168 h measured, but was not corrected. The elimination half-life (t 1/2 ) was calculated as ln 2/l z . The apparent volume of following the second digoxin dose for plasma digoxin assay. Urine was collected up to 24 h after the second digoxin distribution, V z /F, was calculated as Dose. AUC(0, 2)/l z . The aciclovir dose was calculated from the molar equivalents dose, weighed, and a 10 ml aliquot was frozen at −20°C for digoxin assay.
in the valaciclovir dose. Urinary recovery (Ae) was calculated as the product of urine concentrations and weights (assuming Adverse experiences were recorded, 12-lead ECGs were performed before dosing and at 24 h after the second digoxin density of 1 g ml −1 ). Renal clearance (CL R ) was calculated as Ae/AUC where Ae is the amount of drug excreted dose, and continuous lead II ECG monitoring was performed on all subjects for 24 h after digoxin doses.
unchanged in urine, and AUC and Ae were measured over 12 and 24 h for aciclovir and digoxin respectively. Pharmacokinetic parameters following digoxin or valacicloAssays vir alone or in combination were subjected to analysis of Plasma and urine aciclovir determinations were made using variance. All parameters except t max were log-transformed double antibody radioimmunoassay (r.i.a.), which is a prior to analysis. Data were back-transformed to provide a modification of the original method [7] . The lower limits point estimate with 95% confidence interval (CI) for the ratio of quantitation (LLOQs) were 0.01 mg ml −1 (0.04 mm) for in pharmacokinetic parameters between treatments. Differences plasma and 0.025 mg ml −1 (0.11 mm) for urine, with separate between t max medians were estimated (with 95% CIs) using a inter-and intra-assay precision shown by coefficients of method based on the Wilcoxon Signed Rank test. variation (CVs) of <10% for plasma and <11% for urine.
Plasma and urine digoxin determinations were made using Results a competitive r.i.a. procedure (Phoenix International Life Sciences Inc.). The LLOQ was 0.10 ng ml −1 for both plasma and urine, with combined inter-and intra-assay precision Pharmacokinetic and statistical analysis shown by CVs of ≤10% for plasma and ≤12% for urine.
Arithmetic mean±s.d. and geometric mean digoxin pharmacokinetic parameters are given in Table 1 . There were no Pharmacokinetic and statistical analysis clinically significant differences obtained when digoxin was given alone or with valaciclovir (Table 1 ). The total amount Non-compartmental pharmacokinetic parameters were determined for plasma aciclovir and digoxin. The area under of drug excreted in 24 h in urine (n=11) was similar whether digoxin was given alone (73.8±28.5 mg) or in the plasma concentration-time curve from zero to the last measurable plasma concentration AUC(0, t) was estimated combination (81.0±31.3 mg). c Median (range) and median difference (95% CI) shown. Arithmetic mean±s.d. and geometric mean aciclovir digoxin does not share this system indicated by the lack of effect of probenecid and tolazoline on digoxin secretion [5] . pharmacokinetic parameters are given in Table 2 . There were no statistically significant differences obtained when This contrasts with the competitive effects of probenecid and cimetidine on aciclovir secretion following valaciclovir, valaciclovir was given alone or concomitantly with digoxin ( Table 2 ). The percentage of the dose excreted in urine resulting in reduced aciclovir renal clearance [3] . In summary, these data indicate that there is no clinically (n=10) was similar whether valaciclovir was given alone (42.6±9.8%) or in combination (43.5±8.0%).
Short report
significant interaction when valaciclovir and digoxin are coadministered and that the two drugs can be co-prescribed without dosage adjustment.
Adverse experiences (AEs)
There were no clinically significant changes in the ECG, References and no AEs following valaciclovir alone. The most common AE was nausea, a known side-effect of digoxin, with 15
